Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years. In some cases, the neuropathy may progress or become irreversible despite discontinuation of the medications.

MANAGEMENT: Caution is advised during concomitant use of agents with neurotoxic effects. Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage. If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status. In some cases, permanent dosage reductions may be required.

Food may interfere with the absorption of ixazomib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take ixazomib at least 1 hour before or 2 hours after eating. On days when you take both ixazomib and dexamethasone, make sure you do not take them at the same time, since ixazomib should be taken on an empty stomach while dexamethasone should be taken with food to prevent irritation and injury to the stomach.